{"id":"https://openalex.org/W2809713381","doi":"https://doi.org/10.1136/esmoopen-2018-eacr25.488","title":"PO-468 The role of topoisomerase II-\u03b1 (TOPO IIA) as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer","display_name":"PO-468 The role of topoisomerase II-\u03b1 (TOPO IIA) as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer","publication_year":2018,"publication_date":"2018-06-01","ids":{"openalex":"https://openalex.org/W2809713381","doi":"https://doi.org/10.1136/esmoopen-2018-eacr25.488","mag":"2809713381"},"language":"en","primary_location":{"id":"doi:10.1136/esmoopen-2018-eacr25.488","doi":"https://doi.org/10.1136/esmoopen-2018-eacr25.488","is_oa":true,"landing_page_url":"https://doi.org/10.1136/esmoopen-2018-eacr25.488","pdf_url":null,"source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1136/esmoopen-2018-eacr25.488","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044192585","display_name":"Marwa G. Gamea","orcid":"https://orcid.org/0000-0001-9747-5253","observed_orcids":["https://orcid.org/0000-0001-9747-5253"]},"institutions":[{"id":"https://openalex.org/I86310350","display_name":"Aswan University","ror":"https://ror.org/048qnr849","country_code":"EG","type":"education","lineage":["https://openalex.org/I86310350"]}],"countries":["EG"],"is_corresponding":true,"raw_author_name":"M. Gamea","raw_affiliation_strings":["aswan university, clinical oncology, kafr zayat, Egypt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"aswan university, clinical oncology, kafr zayat, Egypt","institution_ids":["https://openalex.org/I86310350"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5044192585"],"corresponding_institution_ids":["https://openalex.org/I86310350"],"apc_list":{"value":3910,"currency":"USD","value_usd":3910},"apc_paid":{"value":3910,"currency":"USD","value_usd":3910},"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"3","issue":null,"first_page":"A206","last_page":"A206"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9765999913215637,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9765999913215637,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.0215000007301569,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/topoisomerase-ii-alpha","display_name":"TOP2A","score":0.9449999928474426},{"id":"https://openalex.org/keywords/anthracyclines","display_name":"anthracyclines","score":0.7490000128746033},{"id":"https://openalex.org/keywords/neoadjuvant-chemotherapy","display_name":"neoadjuvant chemotherapy","score":0.9959999918937683},{"id":"https://openalex.org/keywords/locally-advanced-breast-cancer","display_name":"locally advanced breast cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9419999718666077},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.7649999856948853},{"id":"https://openalex.org/keywords/her2-overexpression","display_name":"HER2 overexpression","score":0.8600000143051147},{"id":"https://openalex.org/keywords/hormone-receptor-status","display_name":"hormone receptor status","score":0.7590000033378601},{"id":"https://openalex.org/keywords/ki-67-proliferation-index","display_name":"Ki-67 proliferation index","score":0.7940000295639038},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.4269999861717224}],"concepts":[{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.7327595353126526},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.632203221321106},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6230936050415039},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5845060348510742},{"id":"https://openalex.org/C147897179","wikidata":"https://www.wikidata.org/wiki/Q407828","display_name":"Topoisomerase","level":3,"score":0.47993236780166626},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43440601229667664},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.41850775480270386},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40001922845840454},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08713248372077942},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.04957655072212219},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/esmoopen-2018-eacr25.488","doi":"https://doi.org/10.1136/esmoopen-2018-eacr25.488","is_oa":true,"landing_page_url":"https://doi.org/10.1136/esmoopen-2018-eacr25.488","pdf_url":null,"source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1136/esmoopen-2018-eacr25.488","doi":"https://doi.org/10.1136/esmoopen-2018-eacr25.488","is_oa":true,"landing_page_url":"https://doi.org/10.1136/esmoopen-2018-eacr25.488","pdf_url":null,"source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4234454891","https://openalex.org/W4230434115","https://openalex.org/W2133023339","https://openalex.org/W2386717267","https://openalex.org/W1989465474","https://openalex.org/W2133238091","https://openalex.org/W1993275731","https://openalex.org/W2369328306","https://openalex.org/W1974552977","https://openalex.org/W2369019116"],"abstract_inverted_index":{"Introduction":[0],"Topoisomerase":[2,90],"II-\u03b1":[3,16,35,133,248],"is":[4,18],"a":[5,244],"molecular":[6],"target":[7],"of":[8,27,190,206],"anthracyclines;":[9],"several":[10],"studies":[11],"have":[12],"suggested":[13],"that":[14],"topoisomerase":[15,34,132,247],"expression":[17,99,249],"related":[19],"to":[20,22,31,39,68],"response":[21,38,166],"anthracycline":[23,40],"treatment.":[24],"The":[25],"objective":[26],"this":[28],"study":[29,55],"was":[30],"evaluate":[32],"if":[33],"overexpression":[36,151],"predicts":[37],"treatment":[41],"in":[42,106,250],"locally":[43,63,116,251],"advanced":[44,64,117,252],"breast":[45,65,109,118,253],"cancer":[46,66,254],"patients.":[47],"Material":[49],"and":[50,79,100,122,146,152,164,171,177,193,198,231,256],"methods":[51],"This":[53],"prospective":[54],"included":[56],"50":[57,112,127],"patients":[58,113,135,187,204,219,255],"with":[59,115,167,260],"primary":[60],"non":[61],"metastatic":[62],"according":[67],"American":[69],"Joint":[70],"Committee":[71],"For":[72],"Cancer":[73],"Staging(T3-4;N0-3)were":[74],"treated":[75],"between":[76,162,246],"(January":[77],"2012":[78],"Jaune":[80],"2012)":[81],"at":[82],"Clinical":[83,184],"Oncology":[84],"Department,":[85],"Tanta":[86],"University":[87],"Hospital.":[88],"II-\u03b1,":[91],"HER2,":[92,194],"oestrogen":[93],"receptor":[94,97,196,229,236],"(ER),":[95],"progesterone":[96],"(PR)":[98],"KI-67":[101],"were":[102],"evaluated":[103],"by":[104],"immunohistochemistry":[105],"formalin-fixed,":[107],"paraffin-embedded":[108],"tumours":[110],"from":[111,126],"presenting":[114],"cancer.":[119],"Results":[121],"discussions":[123],"Tumours":[125],"patients,":[128],"45":[129],"(90%)":[130],"showed":[131],"overexpression,":[134],"34":[136],"(68%)":[137],"for":[138,143,149,155],"ER":[139],"positive,":[140],"32":[141],"(64%)":[142],"PR":[144],"positive":[145,230],"10":[147],"(20%)":[148],"HER2":[150,170],"16":[153],"(32%)":[154],"high":[156,199],"KI":[157],"67.":[158],"Significant":[160],"correlation":[161,245],"clinical":[163,258],"pathological":[165],"topo":[168,191,209],"IIA,":[169],"KI-67.":[172,200],"p":[173],"value":[174],"(\u22640.001),":[175],"(0.005)":[176],"(0.015)":[178],"respectively.":[179],"1-Responders:":[181],"v":[183,202],"(CR):":[185],"3":[186],"had":[188,208,221,227,234],"co-expression":[189],"II":[192],"hormonal":[195,228,235],"negative":[197,222],"Clinical(PR):43":[203],"majority":[205],"them":[207],"IIA":[210],"overexpression.":[211],"fig(9\u201310)":[212],"2-Non":[214],"responders:":[215],"4":[217],"(8%)":[218],"all":[220],"(TOPOII/HER2),":[223],"low":[224],"KI-67and":[225],"2":[226,233],"another":[232],"negative.":[237],"Conclusion":[239],"Our":[241],"data":[242],"support":[243],"improved":[257],"benefit":[259],"neoadjuvant":[261],"anthracyclines":[262],"based":[263],"therapy.":[264]},"counts_by_year":[],"updated_date":"2026-09-09T07:26:56.047234","created_date":"2018-07-10T00:00:00"}